Ubs Group Ag Cardiol Therapeutics Inc. Call Options Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDL
# of Institutions
43Shares Held
6.92MCall Options Held
25.9KPut Options Held
1.7K-
Tejara Capital LTD London, X03.19MShares$3.48 Million1.2% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD857KShares$934,5520.22% of portfolio
-
Pvg Asset Management Corp Golden, CO437KShares$476,7241.99% of portfolio
-
Lion Street Advisors, LLC340KShares$370,6270.15% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9293KShares$319,4310.15% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $67.5M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...